Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

Kuemmel, S; Tondini, CA; Abraham, J; Nowecki, Z; Itrych, B; Hitre, E; Karaszewska, B; Juarez-Ramiro, A; Morales-Vasquez, F; Perez-Garcia, JM; Cardona-Huerta, S; Monturus, E; Sequi, M; Restuccia, E; Benyunes, M; Martin, M

Kuemmel, S (corresponding author), Kliniken Essen Mitte, Breast Unit, Henricistr 92, D-45136 Essen, Germany.; Kuemmel, S (corresponding author), Charite Univ Med Berlin, Clin Gynecol Breast Ctr, Berlin, Germany.

BREAST CANCER RESEARCH AND TREATMENT, ; ():

Abstract

Purpose Intravenous trastuzumab, pertuzumab, and docetaxel are first-line standard of care for patients with HER2-positive metastatic breast cancer (m......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索